Tidepath

The GLP-1 family

Mounjaro

Mounjaro is a brand name for Tirzepatide. This page covers Tirzepatide, the drug in it.

Two hormone receptors instead of one.

Status
Approved by the FDA, as a weekly injection.
How it's taken
By injection
Where doses come from
Doses on the label
Half-life
About 5-6 days

What it is

Tirzepatide is a GIP and GLP-1 receptor agonist: it switches on two receptors, the ones for GLP-1 and GIP. GIP is the other main incretin, one of the small group of gut hormones that tell the pancreas to release insulin. Like GLP-1, it's released by the gut after you eat, but it acts through its own receptor. Acting on both is the whole idea behind the drug.

What makes it distinct

Zepbound is approved to reduce excess weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related health problem, alongside a reduced-calorie diet and more physical activity. Both labels, Zepbound and Mounjaro, offer strengths from 2.5 to 15 mg in steps of 2.5 mg, but they differ on when to move up. The labels offer only those six strengths, so 'somewhere between 7.5 and 10' isn't a dose either label offers.

Doses on the label

Both labels start at 2.5 mg. On Zepbound that's only a starting dose: the label says to go up to 5 mg after four weeks. For weight, its doses to stay on are 5, 10 or 15 mg; for sleep apnea, 10 or 15 mg. Mounjaro no longer calls 2.5 mg a starting dose, and goes up only if blood sugar needs more control. Whenever either label goes up, it's by 2.5 mg, after at least four weeks on the current dose. Neither label goes above 15 mg for adults. Mounjaro's limit for children 10 and older with type 2 diabetes is 10 mg.

Source FDA labels for Mounjaro and Zepbound. Checked 4 Nov 2026.

This describes the source. It isn't advice.

How levels build

Week 024681012
The same dose every week, estimated. Levels build for the first few weeks, then rise and fall in the same weekly pattern. Worked out from the half-life on the label. An estimate of how much is left from past doses, not a blood test.

Open questions

  • How much of the effect comes from the GIP part specifically, rather than from the two together. That's still an open question.
  • Whether it causes thyroid tumors in people. In animal studies it caused thyroid C-cell tumors (C-cells are a type of cell in the thyroid), and its label says it isn't known whether that happens in people.

Put your shot day in your calendar

A weekly reminder in the calendar you already use. It's made on your device; we never see your shot day.

More in The GLP-1 family